Literature DB >> 2066859

Hypercalciuria in children severely affected with osteogenesis imperfecta.

A Chines1, D J Petersen, F W Schranck, M P Whyte.   

Abstract

To investigate our impression that hypercalciuria is relatively common in children with osteogenesis imperfecta, we performed a retrospective study of data accumulated from our pediatric population with this skeletal disorder. Children with osteogenesis imperfecta (17 girls, 30 boys; mean (+/- SD) age 7.8 +/- 4.6 years; range 0.7 to 16.8 years) had undergone detailed inpatient evaluation of mineral homeostasis during periods of clinical stability and controlled dietary calcium intake. Hypercalciuria was found in 36% of the patients and averaged (+/- SEM) 6.1 +/- 0.3 mg/kg per 24 hours (0.15 +/- 0.01 mmol/kg per 24 hours) or 392 +/- 28 mg/gm of creatinine (1.10 +/- 0.07 mmol calcium/mmol creatinine) in the group with hypercalciuria. There were no statistically significant differences in age, gender, or dietary calcium intake (per kilogram of body weight) between the normocalciuric and hypercalciuric children. However, the group with hypercalciuria was shorter than the normocalciuric group and had a greater lifelong fracture rate. When patient height z scores were regressed against urinary calcium levels, a significant negative correlation was found in the group with hypercalciuria (r = -0.76; p less than 0.001). Although serum alkaline phosphatase activity was lower in the group with hypercalciuria, no difference was found between groups with regard to serum levels of calcium, phosphate, magnesium, creatinine, immunoreactive parathyroid hormone, or osteocalcin. The groups were also similar with respect to both their total body mineral density, as determined by dual-photon absorptiometry (n = 17), and their static indexes of bone formation and resorption, as assessed histomorphometrically with iliac crest specimens (n = 19). We conclude that hypercalciuria occurs frequently in children with osteogenesis imperfecta, and that its magnitude appears to reflect the severity of the skeletal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066859     DOI: 10.1016/s0022-3476(05)81038-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

Review 1.  Biphosphonates.

Authors:  J Allgrove
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

2.  Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.

Authors:  C J Williams; R A Smith; R J Ball; H Wilkinson
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

3.  Co-existence of osteogenesis imperfecta and hyperparathyroidism.

Authors:  T Zimmermann-Belsing; A M Lund; L Christensen; U Feldt-Rasmussen
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

4.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

5.  Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.

Authors:  Lena Lande Wekre; Erik F Eriksen; Jan A Falch
Journal:  Arch Osteoporos       Date:  2011-04-14       Impact factor: 2.617

Review 6.  Osteogenesis Imperfecta.

Authors:  Justin Easow Sam; Mala Dharmalingam
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.